WINT — Windtree Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Windtree Therapeutics Reports Second Quarter 2022 Financial Results And Provides Key Business Updates
Brief: Windtree Therapeutics Inc - On June 3, Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Windtree Presents Data From Positive Seismic Phase 2 Study Of Istaroxime
Brief: Windtree Reports Q1 2022 Results And Provides Key Business Updates
U.S. STOCKS ON THE MOVE-OpGen Inc, Anthem Inc, Dow Inc
U.S. STOCKS ON THE MOVE-Procter & Gamble, AlloVir, Netflix
Windtree surges after cardiac shock drug succeeds in study
Brief: Windtree Announces Positive Topline Results From Its Phase 2 Seismic Study Of Istaroxime In Early Cardiogenic Shock
Windtree Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Windtree Therapeutics Reports Q4 Results
Windtree Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Windtree Announces Results From Its Phase 2 Study Of Lucinactant For Covid-19 Associated Acute Respiratory Distress Syndrome And Lung Injury
Brief: Windtree Completes Enrollment Of Phase 2 Study Of Istaroxime In Early Cardiogenic Shock
Brief: Windtree Completes Enrollment In Its Phase 2 Study Of Lucinactant
Brief: Windtree Therapeutics Inc Files For Mixed Shelf Of Up To $100 Million – SEC Filing
Brief: Windtree Announces U.S. Patent And Trademark Office Issuance Of New U.S. Istaroxime Patent
Windtree Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Windtree Therapeutics Posts Quarterly Loss Per Share Of $0.31
Brief: Windtree Announces Notice Of Allowance From U.S. Patent And Trademark Office For New Istaroxime Patent